Evaluation of Efficacy and Safety of miraDry® Procedure in the Treatment of Primary Axillary Hyperhidrosis

IF 2.8 3区医学 Q2 SURGERY Aesthetic Plastic Surgery Pub Date : 2025-01-03 DOI:10.1007/s00266-024-04558-1

Florian Wimmer, Anika Ramic, Jan Philipp Nolte, Gabriel Djedovic, Marion Dietl

{"title":"Evaluation of Efficacy and Safety of miraDry® Procedure in the Treatment of Primary Axillary Hyperhidrosis","authors":"Florian Wimmer, Anika Ramic, Jan Philipp Nolte, Gabriel Djedovic, Marion Dietl","doi":"10.1007/s00266-024-04558-1","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><p>Primary axillary hyperhidrosis significantly impacts the quality of life of affected individuals. miraDry<sup>®</sup>, a non-invasive local precisely controlled thermal energy procedure, represents a promising treatment option. This retrospective analysis aimed to evaluate the treatment success and patient safety following miraDry<sup>®</sup> procedure in the treatment of primary axillary hyperhidrosis.</p><h3>Material and Methods</h3><p>A total of 139 patients receiving miraDry<sup>®</sup> procedure from 2019 to 2023 with miraDry<sup>®</sup> fresh protocol for treatment of excessive axillary hyperhidrosis were analyzed. Subjective assessment was performed before and after treatment using hyperhidrosis disease severity scale (HDSS). Minor test (iodine starch test) was done before treatment and 6 months after treatment to objectively quantify sweat severity. Patients with subjective or objective unsatisfied results after first procedure were scheduled for a second treatment.</p><h3>Results</h3><p>The majority of treated patients (84%) could effectively be treated with one single treatment, while only 16% (<i>n</i> = 22) required a secondary intervention. HDSS after treatment completion (single and double treatment) showed a significant improvement (<i>p </i>< 0.001) in subjective evaluation of the treatment success. Minor tests demonstrated a significant reduction in sweat severity (<i>p</i> < 0.001), with 95% of patients experiencing no or minimal sweating after treatment completion. The miraDry® procedure demonstrated a favorable safety profile with typical and transient treatment reactions that mostly resolved within 6 months (94.2%)</p><h3>Conclusion</h3><p>Our data demonstrate that miraDry<sup>®</sup> procedure is an effective and safe treatment option for primary axillary hyperhidrosis, which results in an immense improvement in quality of life and high satisfaction of affected individuals.</p><h3>Level of Evidence II</h3><p>This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266.</p></div>","PeriodicalId":7609,"journal":{"name":"Aesthetic Plastic Surgery","volume":"49 9","pages":"2545 - 2551"},"PeriodicalIF":2.8000,"publicationDate":"2025-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Aesthetic Plastic Surgery","FirstCategoryId":"3","ListUrlMain":"https://link.springer.com/article/10.1007/s00266-024-04558-1","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"SURGERY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction

Primary axillary hyperhidrosis significantly impacts the quality of life of affected individuals. miraDry^®, a non-invasive local precisely controlled thermal energy procedure, represents a promising treatment option. This retrospective analysis aimed to evaluate the treatment success and patient safety following miraDry^® procedure in the treatment of primary axillary hyperhidrosis.

Material and Methods

A total of 139 patients receiving miraDry^® procedure from 2019 to 2023 with miraDry^® fresh protocol for treatment of excessive axillary hyperhidrosis were analyzed. Subjective assessment was performed before and after treatment using hyperhidrosis disease severity scale (HDSS). Minor test (iodine starch test) was done before treatment and 6 months after treatment to objectively quantify sweat severity. Patients with subjective or objective unsatisfied results after first procedure were scheduled for a second treatment.

Results

The majority of treated patients (84%) could effectively be treated with one single treatment, while only 16% (n = 22) required a secondary intervention. HDSS after treatment completion (single and double treatment) showed a significant improvement (p < 0.001) in subjective evaluation of the treatment success. Minor tests demonstrated a significant reduction in sweat severity (p < 0.001), with 95% of patients experiencing no or minimal sweating after treatment completion. The miraDry® procedure demonstrated a favorable safety profile with typical and transient treatment reactions that mostly resolved within 6 months (94.2%)

Conclusion

Our data demonstrate that miraDry^® procedure is an effective and safe treatment option for primary axillary hyperhidrosis, which results in an immense improvement in quality of life and high satisfaction of affected individuals.

Level of Evidence II

This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

miraDry®手术治疗原发性腋窝多汗症的疗效和安全性评价。

简介：原发性腋窝多汗症显著影响患者的生活质量。miraDry®是一种非侵入性的局部精确控制热能程序，代表了一种很有前途的治疗选择。本回顾性分析旨在评估miraDry®手术治疗原发性腋下多汗症的治疗成功率和患者安全性。材料和方法：对2019年至2023年接受miraDry®手术并采用miraDry®fresh方案治疗过度腋毛多汗症的139例患者进行分析。采用多汗症严重程度量表（HDSS）对治疗前后进行主观评价。治疗前和治疗后6个月进行微量试验（碘淀粉试验），客观量化汗液严重程度。第一次手术后主观或客观结果不满意的患者安排第二次治疗。结果：大多数患者（84%）可以通过单一治疗有效治疗，而只有16% （n = 22）需要二次干预。治疗完成后的HDSS（单次和双次治疗）显示出显著的改善(p®程序是原发性腋下多汗症的有效和安全的治疗选择，其结果是生活质量的巨大改善和患者的高满意度。证据等级ii：本刊要求作者为每篇文章指定证据等级。有关这些循证医学评级的完整描述，请参阅目录或在线作者说明www.springer.com/00266。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Aesthetic Plastic Surgery 医学-外科

CiteScore

4.40

自引率

25.00%

发文量

479

审稿时长

3 months

期刊介绍： Aesthetic Plastic Surgery is a publication of the International Society of Aesthetic Plastic Surgery and the official journal of the European Association of Societies of Aesthetic Plastic Surgery (EASAPS), Società Italiana di Chirurgia Plastica Ricostruttiva ed Estetica (SICPRE), Vereinigung der Deutschen Aesthetisch Plastischen Chirurgen (VDAPC), the Romanian Aesthetic Surgery Society (RASS), Asociación Española de Cirugía Estética Plástica (AECEP), La Sociedad Argentina de Cirugía Plástica, Estética y Reparadora (SACPER), the Rhinoplasty Society of Europe (RSE), the Iranian Society of Plastic and Aesthetic Surgeons (ISPAS), the Singapore Association of Plastic Surgeons (SAPS), the Australasian Society of Aesthetic Plastic Surgeons (ASAPS), the Egyptian Society of Plastic and Reconstructive Surgeons (ESPRS), and the Sociedad Chilena de Cirugía Plástica, Reconstructiva y Estética (SCCP). Aesthetic Plastic Surgery provides a forum for original articles advancing the art of aesthetic plastic surgery. Many describe surgical craftsmanship; others deal with complications in surgical procedures and methods by which to treat or avoid them. Coverage includes "second thoughts" on established techniques, which might be abandoned, modified, or improved. Also included are case histories; improvements in surgical instruments, pharmaceuticals, and operating room equipment; and discussions of problems such as the role of psychosocial factors in the doctor-patient and the patient-public interrelationships. Aesthetic Plastic Surgery is covered in Current Contents/Clinical Medicine, SciSearch, Research Alert, Index Medicus-Medline, and Excerpta Medica/Embase.